Treatment Approach for Androgen Receptor–Indifferent Prostate Cancer
This video covers the treatment approach for patients with androgen receptor–indifferent prostate cancer.
In this video, Ana Aparicio, MD, of the University of Texas MD Anderson Cancer Center, discusses the treatment approach for patients with androgen receptor (AR)-indifferent prostate cancer.
AR-indifferent prostate cancer can include patients with small-cell carcinoma or neuroendocrine tumors, which are often AR-negative, but often these are mixed with disease elements that do express the AR.
Recent data suggests these patients are more likely to response to platinum-based chemotherapy such as carboplatin.
Aparicio gave a presentation on this topic at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
